Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 2,387

— Anti-aging vaccine shows promise in mice — will it work in humans?

“This research is still in the early stages and may be a number of years from being available to patients,” Dr. David Pinato, a clinician scientist at Imperial College London’s Department of Surgery & Cancer and a consultant medical oncologist at Imperial College Healthcare NHS Trust, said in the statement. “But this trial is laying crucial groundwork that is moving us closer towards new therapies that are potentially less toxic and more precise.”

The first person treated in the U.K. arm of the trial wishes to remain anonymous, but said “I was pleased to be offered a chance to take part in a new trial.”

Read more | >

Could cannabis use lead to anxiety disorders? This is what a recent study published in EClinicalMedicine hopes to address as a team of researchers led by the Ottawa Hospital Research Institute examine the connection between cannabis use and anxiety disorders by patients who have had emergency department visits. While this study was limited to Canada, it holds the potential to help researchers, legislators, and the public better understand the long-term risks of cannabis on mental health disorders throughout the world.

For the study, the researchers analyzed health records from 2008 to 2019 for 12,099,144 individuals between 10 and 105 years of age across Ontario, Canada who had no prior history of being diagnosed with an anxiety disorder from any hospital visit and compared this to the general population. In the end, the researchers found that 27.5 percent of individuals who visited a hospital for cannabis use were diagnosed with an anxiety disorder within three years of their hospital visit, whereas only 5.6 percent of the general population experienced the same. Additionally, they found that individuals who visited a hospital for cannabis use also visited a hospital for an anxiety disorder within three years of the initial hospital visit, whereas only 1.2 percent of the general population experienced the same.

“Our results suggest that individuals requiring emergency department treatment for cannabis use were both at substantially increased risk of developing a new anxiety disorder and experiencing worsening symptoms for already existing anxiety disorders,” said Dr. Daniel Myran, who is a Faculty of Medicine in the Department of Family Medicine at the University of Ottawa and lead author of the study.

Read more | >

In the dynamic and fast-paced world of private equity, AI integration is not just a passing trend; it’s a transformative force reshaping the landscape of the industry. As firms navigate the complexities of investments, market analysis, and financial predictions, AI emerges as a beacon of efficiency, insight, and innovation.

Currently, AI’s integration in private equity is impressive but not expansive. Most firms primarily focused on data analysis, deal sourcing, and risk assessment. Firms like KKR & Co. and Blackstone pioneered this industry revolution, leveraging AI to analyze market trends, evaluate potential investments, and enhance decision-making processes. For instance, consider how AI algorithms process vast amounts of data to identify promising investment opportunities. By sifting through global financial reports, news, and company data, AI provides a deeper understanding of risks and rewards, at level of volume and understanding that most human analysts would find overwhelming.

Additionally, private equity firms find AI-driven risk assessment models indispensable. These models predict market fluctuations, assess potential investment hazards, and offer a more nuanced understanding of various sectors. This predictive power allows firms to make more informed decisions, balancing risks with potential returns more effectively.

Read more | >

Massachusetts startup Elemind has raised $12 million to read brainwaves and treat people for sleep disorders, long-term pain, tremors, and to speed up learning rates. Clinical trials show the company’s wearable device can accelerate sleep up to 70% faster, reduce tremors in patients with physiological shaking up to 50%, and boost learning rates.

“We use a wearable neurotech device to read the brain in real time and intercept it in real time with something called neurostimulation,” Elemind co-founder and CEO Meredith Perry told me on a recent TechFirst podcast. “That’s using sound or light or vibration or electricity to stimulate the brain. And when we do that, we can actually guide the brain precisely, and that leads to a behavior change. So like a drug, but much smarter and without the side effects.”

Read more | >